Clinical Trials
22
Active:2
Completed:14
Trial Phases
4 Phases
Phase 1:3
Phase 2:2
Phase 3:6
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials
Phase 4
9 (45.0%)Phase 3
6 (30.0%)Phase 1
3 (15.0%)Phase 2
2 (10.0%)A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Phase 1
Active, not recruiting
- Conditions
- Pneumococcal Infectious Disease
- Interventions
- Biological: Sinovac PCV13
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Sinovac Research and Development Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT06183216
- Locations
- 🇨🇳
Binchuan County Center for Diseases Control and Prevention, Dali, Yunnan, China
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
Phase 3
Completed
- Conditions
- COVID-19
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Sinovac Research and Development Co., Ltd.
- Target Recruit Count
- 1750
- Registration Number
- NCT05381350
- Locations
- 🇨🇳
Huaiyin Center for Disease Control and Prevention, Huai'an, Jiangsu, China
Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose
- Conditions
- COVID-19
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Sinovac Research and Development Co., Ltd.
- Target Recruit Count
- 14000
- Registration Number
- NCT05367895
- Locations
- 🇧🇷
Instituto Nacional de Infectologia Evandro Chagas (INI-FIOCRUZ), Manguinhos, Brazil
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong
Phase 2
Withdrawn
- Conditions
- COVID-19
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Sinovac Research and Development Co., Ltd.
- Registration Number
- NCT05254236
- Locations
- 🇨🇳
Gleneagles Hospital HongKong, Hong Kong, China
Immunogenicity of an Inactivated COVID-19 Vaccine
Phase 4
Completed
- Conditions
- COVID-19
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Sinovac Research and Development Co., Ltd.
- Target Recruit Count
- 395
- Registration Number
- NCT05198336
- Locations
- 🇨🇳
Rushan City Center for Disease Control and Prevention, Weihai, Shandong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found